Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
04:01pm, Tuesday, 21'st Mar 2023
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended Decem
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
04:03am, Thursday, 26'th Jan 2023
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
09:00am, Tuesday, 03'rd Jan 2023
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug application
10:36am, Friday, 02'nd Dec 2022
Broker Wedbush has repeated a 'neutral' stance on biopharma Y-mAbs Therapeutics Inc (NASDAQ:YMAB) following news that the US Food and Drug Administration (FDA) has turned down the company's applicatio
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Call Transcript
05:28pm, Saturday, 12'th Nov 2022
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q3 2022 Earnings Conference Call November 8, 2022 4:00 PM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commerc
3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%
10:27am, Wednesday, 09'th Nov 2022
Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Informa
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022
04:01pm, Wednesday, 02'nd Nov 2022
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that
Y-mAbs Therapeutics shares fall 42% following last week's FDA advisory committee vote
08:52am, Monday, 31'st Oct 2022
Shares of Y-mAbs Therapeutics Inc. YMAB, +0.90% plunged 42.5% in premarket trading on Monday after several banks downgraded the company's stock and a Food and Drug Administration advisory committee vo
YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?
04:31am, Thursday, 29'th Sep 2022
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q2 2022 Results - Earnings Call Transcript
09:11pm, Friday, 12'th Aug 2022
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2022 Results Conference Call August 9, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief
Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q1 2022 Results - Earnings Call Transcript
05:44pm, Saturday, 14'th May 2022
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2022 Results Conference Call May 10, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief C
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Monday, 09'th May 2022
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
04:01pm, Tuesday, 03'rd May 2022
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
04:33pm, Thursday, 28'th Apr 2022
YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
